Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102006052755Aexternal-prioritypatent/DE102006052755A1/en
Application filed by Zedira GmbhfiledCriticalZedira Gmbh
Publication of CY1116251T1publicationCriticalpatent/CY1116251T1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Peptides Or Proteins
(AREA)
Abstract
Η εφεύρεση αφορά πεπτιδικά παράγωγα και πεπτιδομιμητικά ως αναστολείς τρανσγλουταμινασών. Η εφεύρεση αφορά επίσης μεθόδους για την παρασκευή των εν λόγω ενώσεων, φαρμακευτικές συνθέσεις που περιέχουν τις εν λόγω ενώσεις, καθώς και χρήσεις των εν λόγω αναστολέων τρανσγλουταμινασών, ειδικά για τη θεραπευτική αγωγή της κοιλιοκάκης και άλλων νόσων που σχετίζονται με τρανσγλουταμινάσες.The invention relates to peptide derivatives and peptidomimetics as transglutaminase inhibitors. The invention also relates to methods for the preparation of said compounds, pharmaceutical compositions containing said compounds, and uses of said transglutaminase inhibitors, especially for the treatment of celiac disease and other transglutaminase-related diseases.
CY20151100404T2006-11-082015-05-08
MICHAEL SYSTEMS AS TRANSGLUTAMINE SUSPENSIONS
CY1116251T1
(en)
New peptide derivatives and peptidomimetics are transglutaminase inhibitors useful for the treatment or prophylaxis of e.g. celiac disease, fibrosis, thrombosis, neurodegenerative disorders, Huntington's chorea and Parkinson disease
Compounds derived from 2,4-dianilinopyrimidines, protein kinase inhibitors; preparation procedure; pharmaceutical composition; and use for the treatment or prevention of inflammatory diseases, diabetes, and cancer.